We use cookies to help us improve your experience and to provide services like web chat. We also use cookies to measure the effectiveness of public health campaigns and understand how people use the website.

To find out more about cookies and how we use them, please see our privacy policy.

PCSK9 Inhibitors

Repatha (evolocumab) 140 mg solution for injection in Sureclick pre-filled pen is available on the High Tech Drug Scheme from 1 July 2019. A Managed Access Protocol is in place for Repatha. This outlines the criteria that must be satisfied in order for a patient to be approved for reimbursement of Repatha on the High Tech Drug Scheme.

The prescribing of Repatha on the High Tech Drug Scheme will initially be confined to designated clinicians who have agreed to the terms of the HSE-Managed Access Protocol. The clinician should submit an application for individual reimbursement approval for each patient.

A copy of the HSE-Managed Access Protocol for Repatha and the application form for individual reimbursement approval can be found in the Related Files section below. 

Clinical Strategy and Programmes Division